Ezetimibe with Moderate-intensity Statin effective initial treatment option for patients with acute ischemic cerebrovascular disease: Study

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-03-03 17:45 GMT   |   Update On 2024-03-03 17:46 GMT

A recent study published in the Journal of Stroke and Cerebrovascular Diseases found that a moderate-intensity statin combined with ezetimibe could be a potential therapy for high-risk stroke patients. This discovery challenges conventional wisdom regarding high-intensity statin therapy, suggesting a more effective and safer alternative.

This randomized controlled trial involved participants with acute ischemic cerebrovascular disease and compared the efficacy and safety of two lipid-lowering regimens which is moderate-intensity statin with ezetimibe against high-intensity statin alone. The results unveiled that doubling the dosage of statin drugs did not enhance the achievement rate of LDL-C target or provide additional clinical benefits, contrary to the previous assumptions. Instead, it significantly increased the risk of adverse reactions.

The patients receiving the moderate-intensity statin with ezetimibe combination showed remarkable improvements. The study revealed that this regimen not only improved the achievement rate of LDL-C but also led to a higher reduction in LDL-C levels when compared to the high-intensity statin group. The safety profiles between the two groups were comparable that indicates the moderate-intensity statin with ezetimibe could be considered as an initial treatment option for acute ischemic cerebrovascular disease patients.

This study challenges the traditional approach to lipid-lowering therapy in stroke patients. It highlights the potential benefits of a more balanced approach using moderate-intensity statin with ezetimibe by offering both efficacy and safety. This research opens new opportunities for stroke management that provides the clinicians with an alternative strategy to reduce the risk of stroke recurrence without compromising the safety of the patients.

Source:

Lv, X., Liu, X., Peng, Y., Li, W., Wang, J., Chen, X., Lei, J., Tang, C., Luo, S., Mai, W., Cai, Y., Fan, Q., Chenhao, L., & Zhang, L. (2024). Medium-intensity statin with ezetimibe versus high-intensity statin in acute ischemic cerebrovascular disease (MESIA):a randomized clinical trial. In Journal of Stroke and Cerebrovascular Diseases (p. 107647). Elsevier BV. https://doi.org/10.1016/j.jstrokecerebrovasdis.2024.107647

Tags:    
Article Source : Journal of Stroke and Cerebrovascular Diseases

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News